Bronchial Biopsy Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Biopsy Forceps (Durability, Disposable, Reusable), Transbronchial Needle Aspiration (TBNA) Needles (Conventional, EBUS-TBNA), Cytology Brushes), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 619.55 Million
CAGR (2026-2031)	6.97%
Fastest Growing Segment	Biopsy Forceps
Largest Market	North America
Market Size (2031)	USD 928.21 Million

Market Overview

The Global Bronchial Biopsy Devices Market will grow from USD 619.55 Million in 2025 to USD 928.21 Million by 2031 at a 6.97% CAGR. Bronchial biopsy devices are specialized medical instruments utilized during bronchoscopic procedures to harvest pulmonary tissue samples for the histopathological diagnosis of lung cancer and other respiratory pathologies. The market is primarily driven by the escalating global incidence of lung malignancies and chronic airway diseases which necessitate precise and early diagnostic intervention. This demand is further bolstered by a growing clinical preference for minimally invasive procedures that reduce hospitalization times and improve patient safety profiles compared to open surgical alternatives. Illustrating the urgent clinical burden driving this demand, according to the American Cancer Society, in 2024, an estimated 234,580 new cases of lung and bronchus cancer were projected to be diagnosed in the United States.

However, the expansion of the Global Bronchial Biopsy Devices Market faces a significant impediment regarding the substantial costs associated with acquiring and maintaining advanced bronchoscopy systems. Limited reimbursement policies in developing healthcare infrastructures and the high capital investment required for these sophisticated diagnostic tools create financial barriers that restrict widespread adoption. Consequently, these economic constraints may hinder market penetration in cost-sensitive regions despite the rising prevalence of respiratory conditions requiring biopsy.

Key Market Drivers

The Global Bronchial Biopsy Devices Market is fundamentally propelled by the rising global prevalence of lung cancer and chronic respiratory disorders, which directly correlates with an increased volume of diagnostic bronchoscopic procedures. As the burden of pulmonary malignancies grows, healthcare systems are prioritizing early detection strategies that rely heavily on biopsy devices for tissue acquisition and histological analysis. This escalation in disease incidence creates a sustained demand for biopsy forceps, needles, and brushes to confirm diagnoses for suspect nodules efficiently. Substantiating this critical volume driver, according to the World Health Organization, February 2024, in the 'Global cancer burden growing' news release, lung cancer was identified as the most commonly occurring cancer worldwide, with approximately 2.5 million new cases accounting for 12.4% of the total new cancer cases globally.

Technological advancements in robot-assisted and navigational bronchoscopy are concurrently revolutionizing the market by enabling access to previously unreachable peripheral lung lesions. Modern platforms utilize electromagnetic navigation and robotic articulation to guide biopsy tools with high precision, significantly improving diagnostic yield and reducing the need for invasive surgical biopsies. This technological leap drives market growth by encouraging hospitals to upgrade their capital equipment and enabling pulmonologists to perform biopsies on smaller, early-stage nodules with greater confidence. Reflecting this rapid adoption of advanced platforms, according to Intuitive Surgical, October 2024, in the 'Q3 2024 Earnings Call', procedures utilizing the Ion endoluminal system grew by 73% compared to the previous year. The improved efficacy of these interventions is contributing to broader positive outcomes; according to the American Lung Association, in 2024, the national lung cancer survival rate has increased by 26% over the past five years, underscoring the market value of effective biopsy and early detection.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the Global Bronchial Biopsy Devices Market is the substantial economic burden associated with acquiring and maintaining these diagnostic systems. High capital costs create a significant barrier to entry for healthcare facilities, particularly in regions where budget constraints are tight or reimbursement policies are insufficient. When hospitals and clinics face financial instability, they are often forced to prioritize operational expenses over capital investments. This economic pressure leads to a reluctance to purchase new, higher-cost biopsy instruments, causing a direct slowdown in the adoption of advanced technology despite the clear clinical necessity for early lung cancer detection.

Consequently, manufacturers face extended sales cycles and reduced market penetration as potential buyers defer purchasing decisions. According to the American Hospital Association, in 2024, 94 percent of health care administrators expected to delay equipment upgrades to manage financial strain. This statistic highlights a widespread trend where financial limitations directly translate into halted modernization of diagnostic capabilities. As providers postpone the acquisition of essential devices to preserve liquidity, the bronchial biopsy market experiences a contraction in demand, preventing the widespread utilization of these critical tools in patient care.

Key Market Trends

The market is currently witnessing an accelerated shift toward single-use disposable bronchoscopes, fundamentally driven by the critical need to eliminate cross-contamination risks and optimize hospital operational workflows. Unlike traditional reusable instruments, which incur significant costs related to sterilization, repairs, and reprocessing downtime, disposable variants offer immediate availability and a sterile guarantee for every procedure. This transition is further catalyzed by rapid improvements in optical quality and maneuverability, allowing these devices to rival the performance of capital-intensive reusable platforms in intensive care and operating room settings. Highlighting this robust adoption, according to Ambu A/S, November 2024, in the 'Annual Report 2023/24', the company's Endoscopy Solutions segment, which is anchored by its single-use bronchoscopy portfolio, achieved an organic revenue growth of 19.7% for the full financial year.

Concurrently, the convergence of artificial intelligence with real-time tomographic imaging is transforming navigational bronchoscopy by addressing the persistent challenge of CT-to-body divergence. Advanced platforms are now integrating AI-driven path planning with intraoperative fluoroscopic tomosynthesis to provide pulmonologists with augmented, real-time visual guidance that corrects for respiratory motion and target displacement during the biopsy. This technological synergy enables the precise targeting of small, peripheral lung nodules that were previously difficult to localize with standard pre-operative CT mapping alone. Underscoring the clinical efficacy of this innovation, according to Body Vision Medical, June 2024, in the 'LungVision Named Best New Technology Solution - Biopsy in 2024 MedTech Breakthrough Awards Program' press release, their AI-powered imaging system has demonstrated the capability to achieve a diagnostic yield of approximately 90% in bronchoscopic procedures.

Segmental Insights

Based on current market intelligence, the Biopsy Forceps segment is identified as the fastest growing category within the Global Bronchial Biopsy Devices Market. This rapid expansion is primarily driven by the increasing clinical preference for disposable biopsy forceps, which are essential for minimizing cross-contamination risks and ensuring strict infection control during procedures. Furthermore, the rising global incidence of lung cancer necessitates frequent and precise tissue sampling for accurate diagnosis. Data from the World Health Organization highlights the growing burden of respiratory malignancies, a factor that logically reinforces the sustained demand for reliable and sterile biopsy forceps in diagnostic settings.

Regional Insights

North America maintains a dominant position in the global bronchial biopsy devices market, primarily driven by the rising prevalence of respiratory disorders and lung cancer across the United States and Canada. This regional leadership is supported by a well-established healthcare infrastructure that facilitates early disease detection and the adoption of minimally invasive diagnostic procedures. Additionally, favorable reimbursement policies and the presence of major medical device manufacturers strengthen market expansion. The rigorous approval pathways established by the U.S. Food and Drug Administration (FDA) further ensure the consistent availability and safety of these essential diagnostic tools within the region.

Recent Developments

• In August 2025, Intuitive Surgical Korea officially launched the Ion robotic bronchoscopy system in the South Korean market. This robotic-assisted platform was introduced to enable minimally invasive biopsies of lung nodules, specifically targeting lesions in the peripheral lung segments where traditional devices often struggle to navigate. The General Manager of Intuitive Korea described the expansion as a strategic move to advance early cancer diagnosis capabilities in the region. The system features an ultra-thin, articulating catheter designed to move precisely through the airways, allowing clinicians to obtain tissue samples from all 18 segments of the lung.
• In August 2024, Body Vision Medical released a significant software update, version 2.27, for its LungVision navigation and real-time imaging platform. This new version integrated an enhanced AI Tomo imaging algorithm that provided a larger field of view during pulmonary procedures. The company reported that the update improved the fidelity of virtual bronchoscopy in peripheral airways and assisted physicians in better pathway planning. By converting standard X-ray units into intraoperative tomographic imaging systems, the technology aimed to increase the precision of bronchial biopsies and enable definitive diagnoses of lung lesions without requiring expensive new hardware.
• In June 2024, Noah Medical published positive data from a clinical study regarding its Galaxy System in the Asian Pacific Society of Respirology journal. The research demonstrated that the robotic platform achieved a 100% success rate for navigation and 100% tool-in-lesion accuracy during bronchoscopy procedures. The system utilized proprietary technology with integrated tomosynthesis and augmented fluoroscopy to access peripheral lung nodules. This breakthrough research highlighted the device's ability to reliably reach difficult anatomical locations, potentially improving diagnostic yields for lung cancer and addressing limitations often associated with traditional bronchial biopsy methods.
• In May 2024, Olympus announced the launch of two new bronchoscopes, the BF-H1100 and BF-1TH1100, as part of its EVIS X1 Endoscopy System. These devices were introduced to enhance diagnostic and therapeutic capabilities in the respiratory market. The Business Unit Vice President for Respiratory at Olympus Corporation of the Americas noted that the new scopes featured slimmer outer diameters and larger working channels compared to their predecessors. This design improvement was intended to provide pulmonologists with better access to distal airways and increased suction power, thereby facilitating more effective bronchial biopsies and treatment procedures for patients.

Key Market Players

• OLYMPUS CORPORATION
• Boston Scientific Corporation
• Cook Medical Inc
• CONMED Corporation
• Medtronic PLC
• Hobbs Medical Inc
• Telemed Systems Inc
• Becton Dickinson & Co Ltd
• Argon Medical Devices Inc
• Horizons Holdings International Corp

By Product	By Region
Biopsy Forceps (Durability, Disposable, Reusable) Transbronchial Needle Aspiration (TBNA) Needles (Conventional, EBUS-TBNA) Cytology Brushes	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Bronchial Biopsy Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Bronchial Biopsy Devices Market , By Product:

• Biopsy Forceps (Durability, Disposable, Reusable)
• Transbronchial Needle Aspiration (TBNA) Needles (Conventional, EBUS-TBNA)
• Cytology Brushes

• Bronchial Biopsy Devices Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE